DK1993357T3 - Formuleringer af en tight junction effektor - Google Patents

Formuleringer af en tight junction effektor

Info

Publication number
DK1993357T3
DK1993357T3 DK07750332.4T DK07750332T DK1993357T3 DK 1993357 T3 DK1993357 T3 DK 1993357T3 DK 07750332 T DK07750332 T DK 07750332T DK 1993357 T3 DK1993357 T3 DK 1993357T3
Authority
DK
Denmark
Prior art keywords
formulations
tight junction
junction effector
effector
tight
Prior art date
Application number
DK07750332.4T
Other languages
English (en)
Inventor
Blake Paterson
Mark J Ginski Ph D
Original Assignee
Alba Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alba Therapeutics Corp filed Critical Alba Therapeutics Corp
Application granted granted Critical
Publication of DK1993357T3 publication Critical patent/DK1993357T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/009—Sachets, pouches characterised by the material or function of the envelope
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DK07750332.4T 2006-02-09 2007-02-09 Formuleringer af en tight junction effektor DK1993357T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77145406P 2006-02-09 2006-02-09
PCT/US2007/003486 WO2007095092A2 (en) 2006-02-09 2007-02-09 Formulations for a tight junction effector

Publications (1)

Publication Number Publication Date
DK1993357T3 true DK1993357T3 (da) 2014-04-22

Family

ID=38372020

Family Applications (2)

Application Number Title Priority Date Filing Date
DK07750332.4T DK1993357T3 (da) 2006-02-09 2007-02-09 Formuleringer af en tight junction effektor
DK14150323.5T DK2777695T3 (da) 2006-02-09 2007-02-09 Formuleringer til en tight-junction-effektor

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK14150323.5T DK2777695T3 (da) 2006-02-09 2007-02-09 Formuleringer til en tight-junction-effektor

Country Status (20)

Country Link
US (5) US9265811B2 (da)
EP (2) EP1993357B1 (da)
JP (1) JP5398268B2 (da)
KR (1) KR101393652B1 (da)
CN (2) CN101420850A (da)
AR (1) AR060103A1 (da)
AU (1) AU2007215304B2 (da)
BR (1) BRPI0707616A2 (da)
CA (2) CA2838399C (da)
DK (2) DK1993357T3 (da)
ES (2) ES2459018T3 (da)
HK (2) HK1126088A1 (da)
IL (2) IL193344A (da)
MX (1) MX2008010221A (da)
NZ (1) NZ570427A (da)
PH (1) PH12012501912B1 (da)
RU (1) RU2008136208A (da)
TW (1) TWI478721B (da)
WO (1) WO2007095092A2 (da)
ZA (1) ZA200807111B (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE438405T1 (de) * 2000-05-19 2009-08-15 Univ Maryland Verwendung von peptidantagonisten des zonulin zur behandlung von diabetes
ZA200807111B (en) 2006-02-09 2009-11-25 Alba Therapeutics Corp Formulations for a tight junction effector
WO2008043107A2 (en) * 2006-10-06 2008-04-10 Alba Therapeutics Corporation Use of tight junction antagonists to treat inflammatory bowel disease
WO2008052185A2 (en) 2006-10-26 2008-05-02 Alba Therapeutics Corp Materials and methods for the treatment of celiac disease
EP2091551B1 (en) * 2006-11-03 2020-01-15 Alba Therapeutics Corporation Method of treating asthma
US20090088404A1 (en) * 2007-01-31 2009-04-02 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
JP2010523555A (ja) 2007-04-04 2010-07-15 シグモイド・ファーマ・リミテッド 「経口医薬組成物」
US20110201543A1 (en) * 2007-06-29 2011-08-18 Blake Paterson Use of tight junction antagonists in the treatment of acute lung injury and acute respiratory distress
US9051349B2 (en) 2007-11-21 2015-06-09 Alba Therapeutics Corporation Larazotide acetate compositions
EP2062909A1 (en) * 2007-11-21 2009-05-27 SOLVAY (Société Anonyme) Peptide production and purification process
ES2343499B1 (es) * 2007-12-24 2011-06-10 Consejo Superior De Investigaciones Cientificas Microorganismos para mejorar el estado de salud de individuos con desordenes relacionados con la ingesta de gluten.
US8957032B2 (en) 2008-05-06 2015-02-17 Alba Therapeutics Corporation Inhibition of gliadin peptides
CA2762179A1 (en) 2009-05-18 2010-11-25 Sigmoid Pharma Limited Composition comprising oil drops
US20110027342A1 (en) * 2009-07-28 2011-02-03 Msi Methylation Sciences, Inc. S-adenosylmethionine formulations with enhanced bioavailability
US8329208B2 (en) 2009-07-28 2012-12-11 Methylation Sciences International Srl Pharmacokinetics of S-adenosylmethionine formulations
WO2012044960A1 (en) * 2010-10-01 2012-04-05 The Ramaekers Family Trust Enhancement of immune response by transfer factor
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
BR112014024159A2 (pt) 2012-03-29 2017-06-20 Therabiome Llc Formulações de vacina oral específicas do local gastrintestinal , ativas no íleo e apêndice.
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
US9907755B2 (en) 2013-03-14 2018-03-06 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
WO2015154010A1 (en) 2014-04-04 2015-10-08 Perrow Wendy Methods of treating celiac disease with larazotide
AU2015341695B2 (en) 2014-11-07 2021-07-08 Sublimity Therapeutics Limited Compositions comprising cyclosporin
US10993947B2 (en) * 2016-05-18 2021-05-04 Torqur Treatment of skin lesions
RU2765868C2 (ru) * 2016-05-18 2022-02-04 Торкур АГ Лечение неврологических расстройств
WO2018115984A1 (en) 2016-12-19 2018-06-28 Cellix Bio Private Limited Compositions and methods for the treatment of inflammation
EP3579862A4 (en) 2017-02-10 2020-12-23 9 Meters Biopharma, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF A DISEASE ASSOCIATED WITH PERMEABILITY OF INTESTINAL EPITHELIUM
ES2938609T3 (es) 2017-09-20 2023-04-13 Tillotts Pharma Ag Preparación de formas farmacéuticas sólidas que comprenden anticuerpos mediante estratificación de solución/suspensión
EP3755315A4 (en) 2018-02-23 2022-01-05 9 Meters Biopharma, Inc. COMPOUNDS AND METHODS OF TREATING THE PERMEABILITY OF SEALED CONNECTIONS
WO2019165345A1 (en) * 2018-02-23 2019-08-29 Innovate Biopharmaceuticals, Inc. Compositions and methods for treating or preventing intestinal paracellular permeability
US20210361734A1 (en) 2018-03-19 2021-11-25 9 Meters Biopharma, Inc. Compositions and methods for potentiating immune checkpoint inhibitor therapy
WO2020227341A1 (en) * 2019-05-06 2020-11-12 9 Meters Biopharma, Inc. Compositions and methods for treating sjogren's syndrome
WO2021034629A1 (en) * 2019-08-16 2021-02-25 9 Meters Biopharma, Inc. Larazotide formulations
IL300660A (en) * 2020-08-18 2023-04-01 Cephalon Llc Antibodies against PAR-2 and methods of using them

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643602A (en) 1989-11-22 1997-07-01 Astra Aktiebolag Oral composition for the treatment of inflammatory bowel disease
US5395750A (en) 1992-02-28 1995-03-07 Hoffmann-La Roche Inc. Methods for producing proteins which bind to predetermined antigens
AU5615594A (en) 1992-11-13 1994-06-08 Cancer Research Fund Of Contra Costa Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods
JP2996864B2 (ja) 1994-03-30 2000-01-11 寳酒造株式会社 抗体可変領域ｄｎａ
US20020094346A1 (en) * 1995-05-17 2002-07-18 M. D. Henry C. Lin Method and compositions for improving digestion and absorption in the small intestine
US5827534A (en) 1995-05-24 1998-10-27 University Of Maryland At Baltimore Oral dosage composition comprising zonnula occludens toxin and a therapeutic agent for intestinal delivery
US5665389A (en) 1995-05-24 1997-09-09 University Of Maryland At Baltimore Oral dosage composition for intestinal delivery and method of treating diabetes
CA2249742A1 (en) 1996-03-15 1997-09-18 Steven G. Reed Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
US5908825A (en) 1997-01-09 1999-06-01 University Of Maryland At Baltimore Dosage composition for nasal delivery and method of use of the same
US5864014A (en) 1997-02-20 1999-01-26 University Of Maryland At Baltimore Zonula occludens toxin receptor
US5912323A (en) 1997-02-20 1999-06-15 University Of Maryland, Baltimore Zonula occludens toxin receptors
US5945510A (en) 1997-05-21 1999-08-31 University Of Maryland, Baltimore Substantially pure zonulin, a physiological modulator of mammalian tight junctions
US6506577B1 (en) 1998-03-19 2003-01-14 The Regents Of The University Of California Synthesis and crosslinking of catechol containing copolypeptides
US6458925B1 (en) 1998-08-03 2002-10-01 University Of Maryland, Baltimore Peptide antagonists of zonulin and methods for use of the same
US6733762B1 (en) 1998-09-14 2004-05-11 University Of Maryland, Baltimore Method of using Zot to inhibit lymphocyte proliferation in an antigen-specific manner
DE69939748D1 (de) * 1998-11-02 2008-11-27 Elan Pharma Int Ltd Multipartikuläre zusammensetzung von methylphenidat mit modifizierter freisetzung
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
ATE438405T1 (de) * 2000-05-19 2009-08-15 Univ Maryland Verwendung von peptidantagonisten des zonulin zur behandlung von diabetes
WO2002060415A1 (de) * 2001-01-31 2002-08-08 Röhm GmbH & Co. KG Multipartikuläre arzneiform, enthaltend mindestens zwei unterschiedlich überzogene pelletformen
EP1519717B1 (en) * 2002-07-05 2010-09-29 Temrel Limited Controlled release composition
DE10332160A1 (de) * 2003-07-15 2005-02-03 Röhm GmbH & Co. KG Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Peptid- oder Protein-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform
KR20080056318A (ko) 2003-07-15 2008-06-20 유니버시티 오브 메릴랜드, 볼티모어 Ｚｏｔ 및 조눌린에 대한 수용체의 작용제 폴리펩티드
TW200539903A (en) 2004-03-12 2005-12-16 Smithkline Beecham Plc Pharmaceutical formulations
EP1929298A4 (en) 2005-05-13 2008-11-05 Univ Maryland METHOD FOR ASSESSING THE EFFECTIVENESS OF A TREATMENT PLAN
ZA200807111B (en) * 2006-02-09 2009-11-25 Alba Therapeutics Corp Formulations for a tight junction effector
WO2008043107A2 (en) 2006-10-06 2008-04-10 Alba Therapeutics Corporation Use of tight junction antagonists to treat inflammatory bowel disease
WO2008052185A2 (en) 2006-10-26 2008-05-02 Alba Therapeutics Corp Materials and methods for the treatment of celiac disease

Also Published As

Publication number Publication date
MX2008010221A (es) 2009-03-05
US20070196501A1 (en) 2007-08-23
WO2007095092A3 (en) 2008-09-12
ES2459018T3 (es) 2014-05-07
CA2638914C (en) 2014-04-08
TWI478721B (zh) 2015-04-01
ES2700278T3 (es) 2019-02-14
KR20080108986A (ko) 2008-12-16
US20100279954A1 (en) 2010-11-04
AU2007215304A1 (en) 2007-08-23
CN101420850A (zh) 2009-04-29
ZA200807111B (en) 2009-11-25
US8168594B2 (en) 2012-05-01
DK2777695T3 (da) 2018-12-17
PH12012501912A1 (en) 2014-09-08
US9241969B2 (en) 2016-01-26
BRPI0707616A2 (pt) 2011-05-10
IL228532A0 (en) 2013-12-31
RU2008136208A (ru) 2010-03-20
CA2638914A1 (en) 2007-08-23
US20150164978A1 (en) 2015-06-18
CA2838399A1 (en) 2007-08-23
CA2838399C (en) 2017-03-07
PH12012501912B1 (en) 2014-09-08
JP5398268B2 (ja) 2014-01-29
AU2007215304B2 (en) 2012-06-14
NZ570427A (en) 2011-10-28
CN103301070A (zh) 2013-09-18
EP2777695B1 (en) 2018-09-12
EP1993357A4 (en) 2012-08-15
KR101393652B1 (ko) 2014-05-14
HK1126088A1 (en) 2009-08-28
IL193344A (en) 2013-10-31
US9265811B2 (en) 2016-02-23
US20210154260A1 (en) 2021-05-27
EP1993357A2 (en) 2008-11-26
EP1993357B1 (en) 2014-01-22
WO2007095092A2 (en) 2007-08-23
TW200808339A (en) 2008-02-16
US20130122086A1 (en) 2013-05-16
AR060103A1 (es) 2008-05-28
HK1202072A1 (en) 2015-09-18
JP2009527468A (ja) 2009-07-30
EP2777695A1 (en) 2014-09-17
IL193344A0 (en) 2009-08-03

Similar Documents

Publication Publication Date Title
DK1993357T3 (da) Formuleringer af en tight junction effektor
NO2022040I1 (no) pembrolizumab - forlenget SPC
NL350090I2 (nl) flupyradifurone
FR2907877B1 (fr) Jonction tubulaire
ITMI20062368A1 (it) Composizioni erbicide
ATE554130T1 (de) Lichtvernetzbare polyolefinzusammensetzungen
BRPI0811926A2 (pt) Composições herbicidas
DK1981859T3 (da) Fremstilling af delmopinol
FR2913672B1 (fr) Joint thermoscellable
ITRM20060613A1 (it) Treppiede perfezionato
BRPI0814188A2 (pt) Formulações
UY3660Q (es) Camara
DE602008001144D1 (de) Kogenerationssystem
DK2111555T3 (da) Diagnosticering af præeklampsi
DK2117732T3 (da) Frembringelse af partier
DK2097068T3 (da) Formuleringer af peg-interferon-alpha-konjugater
BRPI0815652A2 (pt) Composições herbicidas
DE602007012490D1 (de) Herbizidzusammensetzung
DK2229062T3 (da) Fremgangsmåde til fremstillingen af et hydrolysat
FR2907178B1 (fr) Joint homocinetique
DE602007013423D1 (de) Verbesserte bemalbare thermoplastische zusammensetzungen
UY3657Q (es) Cámara
UY3659Q (es) Camara
FR2897662B1 (fr) Joint homocinetique
UY3658Q (es) Camara